Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 5/20 | 0.33 |
| ▸ | MAOB | P27338 | 5/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PPOX | P50336 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | CASP3 | P42574 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10582955 | 0.82 | PARP1 (0.37) | PARP1MAOAMAOBNPSR1PPOX | |
| SCHEMBL7687363 | 0.81 | PARP1 (0.44) | PARP1MAOAMAOBNPSR1PPOX | |
| SCHEMBL29823991 | 0.81 | PARP1 (0.44) | PARP1MAOAMAOBNPSR1PPOX | |
| SCHEMBL4975643 | 0.81 | PARP1 (0.39) | PARP1MAOAMAOBNPSR1PPOX | |
| SCHEMBL11615863 | 0.81 | SRD5A1 (0.44) | PARP1NPSR1PPOXALDH1A1POLB | |
| SCHEMBL2344039 | 0.75 | PARP1 (0.40) | PARP1MAOAMAOBPPOXALDH1A1 | |
| Ethylene SCHEMBL7198620 | 0.73 | PARP1 (0.47) | PARP1MAOAMAOBNPSR1PPOX | |
| SCHEMBL7024540 | 0.73 | PARP1 (0.38) | PARP1PPOXALDH1A1GSK3BHPGD | |
| SCHEMBL3681061 | 0.73 | PARP1 (0.50) | PARP1MAOAMAOBNPSR1PPOX | |
| SCHEMBL9762715 | 0.72 | MAOA (0.44) | PARP1MAOAMAOBGSK3BCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113402448-B | Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof | 中国船舶重工集团公司第七二五研究所 | 2023-03-17 | — | — | CN | claimed |
| CN-113402448-A | Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof | 中国船舶重工集团公司第七二五研究所 | 2021-09-17 | — | — | CN | claimed |
| CN-113402448-B | Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof | 中国船舶重工集团公司第七二五研究所 | 2023-03-17 | — | — | CN | disclosed |
| CN-113402448-B | Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof | 中国船舶重工集团公司第七二五研究所 | 2023-03-17 | — | — | CN | disclosed |
| CN-113402448-A | Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof | 中国船舶重工集团公司第七二五研究所 | 2021-09-17 | — | — | CN | disclosed |
| CN-113402448-A | Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof | 中国船舶重工集团公司第七二五研究所 | 2021-09-17 | — | — | CN | disclosed |
| EP-3796900-A1 | TRITERPENE AMINE DERIVATIVES | DFH Therapeutics (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-2082041-B1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | disclosed |
| EP-2481408-A2 | New use of glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-5264576-A | Antiserotonin agents, antidepressants and obsessive-compulsive disorders | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-11-23 | — | — | US | disclosed |
| CN-1071333-A | CALCIUM RECEPTOR ACTIVE MOLECULES | NPS PHARMA INC (US) | 1993-04-28 | — | — | CN | disclosed |
| WO-1993004373-A1 | CALCIUM RECEPTOR ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993000906-A1 | MUSCARINIC ANTAGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-01-21 | — | — | WO | disclosed |
| US-5021429-A | Histamine h2-antagonists; antisecretory-antiallergen agent; skin disorders and peptic ulcers | ALLEN & HANSBURYS LIMITED (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4613695-A | ANTITUMOR | AKTIEBOLAGET LEO (SE) | 1986-09-23 | — | — | US | disclosed |
| EP-0194046-A1 | Dihydropyridine alkanol amines, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-09-10 | — | — | EP | disclosed |
| US-4568685-A | THROMBOXANE SYNTHETASE ENZYME INHIBITORS, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| US-4038412-A | ANTI-VIRAL AGENTS | RICHARDSON-MERRELL INC. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | CASR, CALCR, ORAI1 | PARP1 2764/4885MAOA 4636/4885MAOB 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.